Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cobra Biologics and Alligator Bioscience Extend Drug Development Partnership | Contract Pharma

What are you searching for?

Sign in
Breaking News

Cobra Biologics and Alligator Bioscience Extend Drug Development Partnership

Project will deliver second cell line for manufacture of immuno-oncology antibody ADC-1015 following ADC-1013 success

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cobra Biologics, an international CDMO of biologics and pharmaceuticals, has been contracted to develop a second cell line for Alligator Bioscience AB, a Swedish biotechnology company.

Alligator has requested further support from the team at Cobra to develop the cell line for production of new drug candidate ADC-1015, a bispecific immune activator developed to induce superior immune activation. Cobra is using their expression system maxXpress, along with a historically documented master cell bank (CHO-S) and chemically defined media. This delivers a time saving cell line development and clone selection process suitable for GMP manufacture.

In May 2015 Cobra released details of it’s involvement in manufacturing immuno-oncology antibody ADC-1013, as part of Alligator’s Phase 1 trial in advanced solid tumours.

“Cobra has been manufacturing protein therapeutics since 1995 and our maximum protein expression platform, maxXpress, has proven to be very popular to customers looking for both speed and quality,” said Peter Coleman, chief executive officer, Cobra Biologics. “I am delighted that Cobra has the opportunity to continue working with Alligator on their promising clinical programs.”

“Alligator has a long-standing and successful collaboration with Cobra and has seen very good results using their maxXpress system,” said Per Norlén, chief executive officer, Alligator Bioscience. “We are very happy to continue the collaboration with Cobra on our ADC-1015 drug development program.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics